Hartford Funds Management Co LLC Buys 251 Shares of AstraZeneca PLC (NASDAQ:AZN)

Hartford Funds Management Co LLC increased its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 2.4% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 10,640 shares of the company’s stock after purchasing an additional 251 shares during the period. Hartford Funds Management Co LLC’s holdings in AstraZeneca were worth $829,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in AZN. CANADA LIFE ASSURANCE Co grew its position in shares of AstraZeneca by 40.6% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after purchasing an additional 146 shares in the last quarter. Toronto Dominion Bank raised its holdings in shares of AstraZeneca by 15.2% in the 1st quarter. Toronto Dominion Bank now owns 18,493 shares of the company’s stock valued at $1,253,000 after acquiring an additional 2,447 shares in the last quarter. Silvercrest Asset Management Group LLC raised its holdings in shares of AstraZeneca by 65.5% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 39,915 shares of the company’s stock valued at $2,704,000 after acquiring an additional 15,794 shares in the last quarter. Kennedy Capital Management LLC bought a new stake in shares of AstraZeneca during the 1st quarter valued at about $914,000. Finally, B. Riley Wealth Advisors Inc. grew its holdings in shares of AstraZeneca by 36.0% during the first quarter. B. Riley Wealth Advisors Inc. now owns 23,504 shares of the company’s stock worth $1,592,000 after purchasing an additional 6,224 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Up 2.1 %

AZN opened at $65.63 on Friday. The company has a market cap of $203.49 billion, a P/E ratio of 31.40, a P/E/G ratio of 1.20 and a beta of 0.47. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68. The business’s 50-day moving average price is $73.44 and its 200-day moving average price is $77.80. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. The company had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. AstraZeneca’s revenue was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.87 EPS. On average, equities analysts expect that AstraZeneca PLC will post 4.1 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. TD Cowen upped their target price on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday. Finally, Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.